L-Asparagine: A Comprehensive Reference
1. Identity: Chemical Names, Physical Properties, and Forms
L-Asparagine (symbol Asn or N) is an α-amino acid classified as a polar, aliphatic, non-essential amino acid in mammals. It is an α-amino acid used in the biosynthesis of proteins. Its chemical formula is H₂N-CO-CH₂-CH(NH₂)-COOH, or more generally C₄H₈N₂O₃. It has a molar mass of 132.119 grams per mole. Under standard conditions, asparagine has a white, crystalline appearance. The density of the compound corresponds to 1.543 g/cm³. It is somewhat soluble in water, with a solubility of 2.94 g/100 mL.
L-Asparagine bears a number of synonyms recognized by scientific nomenclature bodies, including: (−)-Asparagine; Agedoite; Altheine; (S)-2,4-Diamino-4-oxobutanoic acid; Asparamide; α-Aminosuccinamic acid; and L-β-Asparagine. Its IUPAC systematic name is 2-amino-3-carbamoylpropanoic acid; its CAS registry number is 70-47-3. Its three-letter code is Asn, its one-letter code is N.
Structurally, asparagine is similar in structure to aspartic acid, but has carboxamide as the side chain's functional group. Asparagine has a carboxamide group (–CONH₂), which is neutral; in contrast, aspartic acid has a carboxylic acid group (–COOH), making aspartic acid an acidic amino acid while asparagine remains a neutral amino acid. At biologically suitable pH levels, asparagine is polar, neutral, and uncharged.
Only one stereoisomer is biologically active: in asparagine, only the L-stereoisomer is involved in synthesis of mammalian proteins. An intriguing chirality-dependent property has been reported: (R)-asparagine (D-Asn) elicits a sweet taste, but (S)-asparagine (L-Asn) induces a bitter taste in humans.
From the aspect of genetic code during protein synthesis, L-asparagine is encoded by the codons AAU and AAC.
Common Forms and Preparations
L-Asparagine is commercially available as a white crystalline powder (monohydrate or anhydrous free base) and is used in pharmaceutical-grade and food-grade preparations, as a biochemical reagent, and as a component in cell culture media. It is a supplement often used in cell culture media to promote cell growth. Beyond naturally occurring L-asparagine, numerous synthetic derivatives have been created to boost its applicability in research and industrial fields, broadening potential uses in pharmaceuticals, biotechnology, and the food industry.
2. Historical Discovery and Traditional Use
L-Asparagine holds the unique distinction of being the first amino acid ever isolated. It was first isolated in 1806 in a crystalline form by French chemists Louis Nicolas Vauquelin and Pierre Jean Robiquet (then a young assistant). It was isolated from asparagus juice, in which it is abundant — hence the chosen name — and was the first amino acid to be isolated. They discovered asparagine after observing cubic crystals in the sap of asparagus, first noted by Delaville in 1802.
Three years later, in 1809, Pierre Jean Robiquet identified a substance from liquorice root with properties which he qualified as very similar to those of asparagine, and which Plisson identified in 1828 as asparagine itself. The determination of asparagine's full structure required decades of further research.
Unlike many herbal or botanical ingredients used as supplements, L-asparagine does not carry a distinct record of deliberate traditional medicinal use as an isolated compound across recognized ethnobotanical or pharmacopoeial traditions. Its history is principally one of biochemical discovery rather than folk or traditional medicine. The compound occurs naturally and ubiquitously in foods that have been consumed across cultures for millennia — asparagus, legumes, grains — but its specific therapeutic exploitation as an isolated amino acid began only in the twentieth century, particularly in the context of cancer chemotherapy.
3. Natural Sources and Dietary Occurrence
L-Asparagine is a nonessential amino acid that naturally occurs in many raw plants. Plants associated with a high L-asparagine level are potatoes, cereal grains (wheat, oat, rye, maize, rice, etc.), coffee beans, vegetables (asparagus, bell paprika, onion, broccoli, lupin, pumpkin), fruit (plum, buckthorn), other plants (chicory, green tea, etc.), and seeds (peanuts, soybean).
Common dietary sources of asparagine include asparagus, dairy products, potatoes, beef, poultry, meat, and eggs. Asparagine found in animal sources includes seafood, fish, eggs, dairy products, and lactalbumin.
The content of free L-asparagine depends on many factors and varies by species, variety, seasonal changes, and other agronomical factors such as fertilization, harvest time, and storage conditions. Plants accumulate L-asparagine during periods when there is a plentiful supply of reduced nitrogen and a shortage of soluble carbohydrates; L-asparagine accumulation can be stimulated by external stresses that increase the proportion of reduced nitrogen to carbon.
4. Biosynthesis: How the Body Makes L-Asparagine
In humans, the L-isomer of asparagine is one of the 20 standard amino acids common in animal proteins and required for normal functioning; however, asparagine is considered a "non-essential amino acid" since it does not have to be taken in with the diet but can be synthesized by the human body from other compounds — specifically, synthesized from aspartic acid.
The precursor to asparagine is oxaloacetate. Oxaloacetate is converted to aspartate (aspartic acid) using a transaminase enzyme; the enzyme transfers the amino group from glutamate to oxaloacetate, producing α-ketoglutarate and aspartate. Asparagine is then synthesized from aspartic acid and ammonia by the enzyme asparagine synthetase, through ATP-dependent amidotransferase reactions.
L-Asparagine is required by all cells for their protein synthesis and healthy growth, but is classified as a nonessential amino acid because normal mammalian cells obtain most of the asparagine they need through their own synthesis.
Although L-asparagine can be obtained from food intake, the molecule cannot freely pass through the blood-brain barrier to enter the brain. This is important because the amino acid is a precursor of aspartic acid, a neurotransmitter and neuromodulator. Therefore, brain cells mainly depend on local asparagine synthesis.
5. Key Constituents and Established Mechanisms of Action
5.1 Structural Role in Proteins
Because it is an amino acid, L-asparagine is a component of many proteins. In cellular proteins, the terminal amine group of the carboxamide side chain of L-asparagine makes efficient hydrogen bond interactions with the peptide backbone; it is therefore often found near the ends of alpha-helices and in turn motifs in beta sheets.
5.2 N-Linked Glycosylation
One of the most biologically critical functions of L-asparagine residues is their role as the attachment site for N-linked glycosylation, a conserved post-translational modification. N-linked glycosylation is the attachment of an oligosaccharide (glycan) to the amide nitrogen of an asparagine residue of a protein. This process involves the sequential assembly of an oligosaccharide onto a polyisoprenyl donor, followed by the en bloc transfer of the glycan to particular asparagine residues within acceptor proteins; these N-linked glycans play a critical role in a wide variety of biological processes, such as protein folding, cellular targeting and motility, and the immune response.
This process involves the assembly of an oligosaccharide on a lipid carrier (dolichylpyrophosphate) and the transfer of the oligosaccharide to selected asparagine residues of polypeptides that have entered the lumen of the endoplasmic reticulum (ER). The assembly requires the activity of several specific glycosyltransferases, and the oligosaccharyltransferase (OST) selects N-X-S/T sequons (the recognition sequence on the polypeptide) to generate the N-glycosidic linkage between the side chain amide of asparagine and the oligosaccharide. This modification is essential for specific molecular recognition, protein folding, sorting in the endoplasmic reticulum, cell–cell communication, and stability.
Defects in N-linked glycosylation result in a class of inherited diseases known as congenital disorders of glycosylation (CDG).
5.3 Nitrogen Transport and Storage in Plants
In plants, asparagine serves a distinct and critical role. Asparagine is a more efficient compound for nitrogen transport and storage compared to glutamine because of its higher N:C ratio. Furthermore, asparagine is more stable than glutamine and can accumulate to higher levels in vacuoles. In plants that have high nitrogen assimilatory capacities, asparagine appears to play a dominant role in the transport and metabolism of nitrogen. In many plants, asparagine is a major recipient of glutamine nitrogen and provides a mobile reservoir for transport to sites of growth.
5.4 Ammonia Transport and Glucogenic Function in Mammals
Asparagine serves as a non-toxic vehicle for the excretion of leftover ammonia from the body and functions as the transport and storage form for nitrogen. Asparagine has three major functions: (1) incorporation into amino acid sequences of proteins; (2) storage form for aspartate, which is a required precursor for synthesis of DNA, RNA, and ATP; and (3) source of amino groups for production of other dispensable amino acids via transaminases.
Asparagine is also a glucogenic amino acid, produced by the liver. In a reaction that is the reverse of its biosynthesis, asparagine is hydrolyzed to aspartate by asparaginase; aspartate then undergoes transamination to form glutamate and oxaloacetate from alpha-ketoglutarate, with oxaloacetate entering the citric acid cycle (Krebs cycle).
5.5 Role in Brain and Nervous System
The non-essential amino acid asparagine has a role in the metabolic regulation of cellular activities in brain and nerve tissue. Asparagine synthetase is required for normal development of the brain. The nervous system needs asparagine to maintain equilibrium, as well as in amino acid transformation.
6. Scientific Evidence by Area of Use
6.1 Asparagine Synthetase Deficiency (ASD): Neurological Disease
The clearest direct clinical evidence linking L-asparagine to human health comes from studies of asparagine synthetase deficiency (ASD), a rare inborn error of metabolism. Asparagine synthetase deficiency is a rare inborn error of metabolism caused by a defect in ASNS (the gene encoding asparagine synthetase). It manifests with a severe neurological phenotype including severe developmental delay, congenital microcephaly, spasticity, and refractory seizures.
Asparagine synthetase deficiency is a condition that causes neurological problems starting soon after birth. Most people with this condition have an unusually small head size (microcephaly) that worsens over time due to loss (atrophy) of brain tissue. They also have severe developmental delay that affects both mental and motor skills. Affected individuals cannot sit, crawl, or walk and are unable to communicate verbally or nonverbally. The few affected children who achieve developmental milestones often lose these skills over time (developmental regression).
The landmark genetic study by Ruzzo et al. (2013, Neuron) analyzed four families that presented with a similar condition characterized by congenital microcephaly, intellectual disability, progressive cerebral atrophy, and intractable seizures, and showed that recessive mutations in the ASNS gene are responsible for this syndrome; two of the identified missense mutations dramatically reduced ASNS protein abundance, suggesting that the mutations cause loss of function. Hypomorphic Asns mutant mice had structural brain abnormalities, including enlarged ventricles and reduced cortical thickness, and showed deficits in learning and memory mimicking aspects of the patient phenotype; ASNS encodes asparagine synthetase, which catalyzes the synthesis of asparagine from glutamine and aspartate, and the neurological impairment may be explained by asparagine depletion in the brain or by accumulation of aspartate/glutamate leading to enhanced excitability and neuronal damage.
Children with mutations in the ASNS gene exhibit developmental delays, intellectual disability, microcephaly, intractable seizures, and progressive brain atrophy. As of the review period, 15 unique mutations in the ASNS gene have been clinically associated with asparagine synthetase deficiency. A larger Saudi Arabian study reported on 13 families: the major phenotypes included congenital microcephaly (100%), facial dysmorphism (100%), global developmental delay (100%), brain abnormalities (100%), spasticity (86%), and infantile-onset seizures (93%).
Evidence for oral L-asparagine supplementation in ASD (clinical, very limited): One published case report from Sprute et al. (2019, Human Genome Variation) described two siblings in whom oral asparagine supplementation was attempted in both patients for 24 months after identification of the metabolic defect. Supplementation was well tolerated, and no further disease progression was observed during treatment. One patient showed mild developmental progress with increased levels of attention and improved nonverbal communication. However, these results were described as supporting further investigation of asparagine supplementation as a treatment option for ASNSD, not as confirming efficacy. A contrasting case also exists in the literature: Alrifai and Alfadhel tested asparagine supplementation (500 mg, once daily) in a child with ASNSD and unfortunately reported worsening seizures leading to discontinuation of the supplementation. Half of the patients reported in the literature died during their first years; there is no effective treatment to date, and only supportive therapy can be offered.
Evidence strength: Extremely limited — only isolated case reports; no controlled clinical trials. ASD is a rare disease affecting a small number of described patients worldwide. The evidence on oral asparagine supplementation is anecdotal and contradictory.
6.2 Acute Lymphoblastic Leukemia (ALL) and Cancer Metabolism
The relationship between L-asparagine and leukemia is one of the best-characterized examples of amino acid auxotrophy in cancer and underpins an established therapeutic strategy — L-asparaginase chemotherapy — which depletes circulating L-asparagine to starve leukemic cells. This section discusses the mechanistic and clinical evidence for asparagine's role in cancer, noting that the established treatment involves depletion of L-asparagine rather than supplementation.
Lack of ASNS protein expression is a hallmark of Acute Lymphoblastic Leukemia (ALL) blasts, which are therefore auxotrophic for asparagine. This peculiarity is the rationale for the use of bacterial L-asparaginase (ASNase) for ALL therapy — the first example of anti-cancer treatment targeting a tumor-specific metabolic feature.
ASNS is poorly expressed in leukemic cells, which rely on serum asparagine to fulfill the increased demand of sustained malignant cell growth and proliferation. L-asparaginase is an amidase that removes serum asparagine from circulation by hydrolyzing L-asparagine into aspartic acid and ammonia; without an exogenous source of asparagine, protein synthesis is quickly inhibited in the tumor cell, subsequently leading to apoptosis.
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age. L-asparaginase is an integral component of treatment for patients with ALL and, since its introduction into pediatric treatment protocols in the 1960s, survival rates in children have progressively risen to nearly 90%.
Other hematological and solid cancers express low levels of ASNS and therefore should also be asparagine auxotrophs and ASNase sensitive. Asparagine metabolism has gained much attention in recent years as a novel target for cancer therapy. Asparagine is widely used in the production of other nutrients and plays an important role in cancer development. Nutritional inhibition therapy targeting asparagine has been used as an anticancer strategy and has shown success in the treatment of leukemia. However, in solid tumors, asparagine restriction alone does not provide ideal therapeutic efficacy.
6.3 Breast Cancer Metastasis and Dietary Asparagine
A high-profile 2018 study published in Nature (Knott et al.) examined the role of asparagine bioavailability in breast cancer metastasis using mouse models. Asparagine synthetase expression in a patient's primary tumour was most strongly correlated with later metastatic relapse, and asparagine bioavailability was shown to strongly influence metastatic potential. Limiting asparagine by knockdown of asparagine synthetase, treatment with L-asparaginase, or dietary asparagine restriction reduces metastasis without affecting growth of the primary tumour, whereas increased dietary asparagine or enforced asparagine synthetase expression promotes metastatic progression.
In a mouse model of breast cancer, asparagine bioavailability strongly influences metastasis and this is correlated with the production of proteins that regulate the epithelial-to-mesenchymal transition; the authors show that asparagine availability promotes an epithelial-to-mesenchymal transition, a process that has been linked to metastasis.
Evidence strength: Preclinical (mouse models and in vitro). These findings are mechanistically important but have not been validated in human clinical trials. Whether dietary modification of asparagine intake translates to altered metastatic risk in human breast cancer patients remains to be established.
6.4 Protein Synthesis, Glycoprotein Biosynthesis, and Cellular Function
L-Asparagine plays an important role in the biosynthesis of glycoproteins and other proteins as a beta-amido derivative of aspartic acid. It is crucial for the synthesis of many proteins and significantly contributes to the biosynthesis of glycoproteins, which are simple proteins linked to sugars. These functions are fundamental to virtually all cellular processes but represent constitutive roles of the amino acid rather than pharmacological actions of supplemental asparagine in healthy individuals.
7. Body Systems Associated with L-Asparagine
- Central Nervous System: Asparagine synthetase is required for normal development of the brain. The severe neurological phenotype of ASD illustrates the essentiality of local asparagine synthesis in the brain, as L-asparagine cannot freely pass through the blood-brain barrier; therefore, brain cells mainly depend on local asparagine synthesis.
- Hematopoietic and Lymphoid System: The dependence of leukemic lymphoblasts on circulating asparagine for protein synthesis and survival underpins ALL chemotherapy. L-asparaginase is successfully integrated into multi-agent chemotherapy regimens to treat both childhood and adult T-cell and B-cell acute lymphoblastic leukemias and NK/T-cell lymphomas by triggering starvation and selective apoptosis of asparagine-addicted cancer cells.
- Hepatic (Liver) System: Asparagine is a glucogenic amino acid produced by the liver, contributing via oxaloacetate to the gluconeogenic pathway.
- Immune and Secretory Protein System: N-linked glycans — for which asparagine residues are the attachment sites — play a critical role in protein folding, cellular targeting and motility, and the immune response.
- Nitrogen Metabolism: Asparagine serves as a non-toxic vehicle for the excretion of leftover ammonia from the body.
8. Acrylamide Formation: An Indirect Food Safety Consideration
A well-established and toxicologically significant process involving L-asparagine is its participation as a direct precursor in the formation of acrylamide during high-temperature food processing. Acrylamide is formed between reducing sugars such as glucose and L-asparagine due to frying, baking, or grilling starchy foods at over 120 °C in low humidity conditions, through a non-enzymatic process called the Maillard reaction. Interest in plant asparagine has grown substantially following the report that acrylamide — a neurotoxin and potential carcinogen — is present in cooked foods, particularly carbohydrate-rich foods such as wheat and potatoes subjected to roasting, baking, or frying at high temperatures; subsequent studies showed that acrylamide could be formed in foods by the thermal degradation of free asparagine in the presence of sugars in the Maillard reaction.
Heating a mixture of asparagine and reducing sugars or other source of carbonyls produces acrylamide in food; these products occur in baked goods such as French fries, potato chips, and toasted bread. Acrylamide is converted in the liver to glycidamide, which is a possible carcinogen.
According to the European Food Safety Authority (EFSA), foods related to human-consumed acrylamide are primarily fried potato products, bakery products, and coffee. This consideration pertains to L-asparagine as a naturally occurring food constituent, not as a supplemental ingredient per se.
9. Dosage Forms and Reported Dosages
As an isolated dietary supplement, L-asparagine is commercially available in capsule and powder form for oral administration. No broadly established or regulatory-approved supplemental dosage range exists for healthy individuals. Published reports and the limited clinical literature document the following specific uses:
- Asparagine Synthetase Deficiency (oral supplementation, pediatric case reports): One reported case tested asparagine supplementation at 500 mg, once daily, in a child with ASNSD. In the Sprute et al. case series, oral asparagine supplementation was attempted in two patients for 24 months, though the specific dose administered is not specified in the available abstract/summary data. Both experiences represent anecdotal case reports rather than dosing from controlled trials.
- Cell culture / biochemical research use: L-asparagine is used as a supplement in cell culture media to promote cell growth, but concentrations used in laboratory settings are not translatable to human supplemental dosing.
No pharmacopoeial monograph (USP, European Pharmacopoeia, WHO) or government body (NIH ODS, EFSA) currently issues a recommended dietary allowance, tolerable upper intake level, or evidence-based therapeutic dosage range for supplemental L-asparagine in humans.
10. Safety Considerations and Interactions
10.1 General Safety of L-Asparagine as a Nonessential Amino Acid
L-Asparagine is required by all cells for their protein synthesis and healthy growth, but is classified as a nonessential amino acid because normal mammalian cells obtain most of the asparagine they need through their own synthesis. Under normal physiological conditions, dietary intake supplements an endogenous supply that is generally adequate.
10.2 Asparagine Supplementation in ASD: Contradictory Evidence
The available case report evidence for oral asparagine supplementation in ASD is contradictory and highlights a real safety concern: asparagine supplementation was well tolerated and no further disease progression was observed in one case series; however, in another reported case, asparagine supplementation (500 mg once daily) in a child with ASNSD led to worsening seizures and discontinuation of the supplementation. These opposing outcomes underscore the absence of controlled clinical evidence and the individualized and unpredictable nature of response.
10.3 Asparagine and Cancer: A Critical Consideration
Research in both hematologic and solid malignancies raises a conceptually important safety consideration regarding asparagine availability. Asparagine bioavailability strongly influences metastatic potential; increased dietary asparagine or enforced asparagine synthetase expression promotes metastatic progression, at least in preclinical breast cancer models. Cancer cells need an increased quantity of L-asparagine compared to non-cancerous cells. Asparagine auxotrophy not only results in sensitivity to asparagine depletion and to ASNase treatment, but also entails a strict dependence of cancer cells on extracellular sources of the amino acid even under normal growth conditions. While these findings are currently preclinical, they suggest that supplemental asparagine warrants caution in the oncological context.
10.4 Interaction with L-Asparaginase Chemotherapy
L-asparaginase, an enzyme not found in humans, depletes serum levels of L-asparagine; as leukemic cells are unable to synthesize this amino acid, its deprivation results in cell death. Exogenous supplementation of L-asparagine would directly antagonize the therapeutic mechanism of asparaginase-based chemotherapy regimens (e.g., Elspar®, Oncaspar®, Erwinaze®). Any residual asparagine can cause treatment failure or cancer recurrences. Therefore, L-asparagine supplementation is pharmacologically contraindicated concurrently with asparaginase chemotherapy.
10.5 Acrylamide Precursor
As noted above, acrylamide — a potential carcinogen and a product of the Maillard reaction — is formed under food processing predominantly from asparagine and reducing sugars at temperatures over 120 °C. This is a consideration for L-asparagine as a food constituent subjected to high-heat cooking, not for cold-process supplemental preparations.
10.6 Blood-Brain Barrier Limitation
Although L-asparagine can be obtained from food intake, the molecule cannot freely pass through the blood-brain barrier to enter the brain. This pharmacokinetic property limits the ability of oral supplementation to correct brain asparagine deficiency in disorders such as ASD, and may contribute to the failure of supplementation to produce robust neurological benefits in affected patients.
References
Volver